What Is KPV Peptide? A Research Overview of the Lys-Pro-Val Tripeptide

KPV is a three amino acid peptide built from lysine, proline, and valine. It corresponds to residues 11 to 13 at the tail end of alpha melanocyte stimulating hormone, and it has attracted growing interest across preclinical research on inflammation and inflammatory signaling at epithelial barriers. Everything below describes the compound and the published record, framed strictly for research use only.

Key Takeaways

• KPV is a tripeptide (Lys-Pro-Val) corresponding to residues 11 to 13 of alpha melanocyte stimulating hormone, with a molecular formula of C16H30N4O4.
• In intestinal epithelial and immune cells, KPV is taken up through the PepT1 di/tripeptide transporter, whose expression rises with colonic inflammation.
• NF-kB reporter activity and pro-inflammatory cytokine transcript levels are the endpoints most frequently measured in KPV cell culture work.
• Anti inflammatory activity has been recorded for KPV in murine DSS colitis, TNBS colitis, and CD45RB transfer colitis models.
• KPV is not FDA approved. The published record consists of in vitro systems, animal models, delivery-system chemistry, and analytical characterization.

What Is KPV Peptide at the Structural Level

KPV is one of the shortest peptides in the melanocortin literature. Just three amino acids, three residues, one sequence: lysine, proline, valine.

Peptides are short chains of amino acids joined by peptide bonds, and most run from a handful of residues to several dozen. KPV sits at the extreme short end.

The sequence comes directly from the parent hormone. Alpha melanocyte stimulating hormone is thirteen residues long, and its final three amino acids are lysine, proline, and valine.

That relationship explains the history of the fragment: work on the parent hormone in the 1990s and 2000s asked which portion carried anti inflammatory activity and which carried pigmentation signaling.

The Molecular Profile of a Three Amino Acid Peptide

The molecular formula is C16H30N4O4. Lysine contributes a basic side chain, proline introduces a rigid ring that constrains the backbone, and valine contributes a branched hydrophobic side chain.

Small size has consequences in an assay. A tripeptide can cross membranes through peptide transporters rather than relying on receptor binding at the cell surface.

The proline residue also affects stability. Proline-containing sequences resist some peptidases, which is one reason short melanocortin fragments were carried forward in preclinical research rather than abandoned.

Analytical characterization is where regulatory attention has landed. FDA has treated KPV free base and KPV acetate as separate substances and has raised naming and quality-characterization questions about both.

How KPV Relates to Alpha Melanocyte Stimulating Hormone

Alpha melanocyte stimulating hormone is a melanocortin peptide derived from proopiomelanocortin. Two distinct activities are attributed to it in the literature: pigmentation signaling and modulation of inflammation.

The full sequence is SYSMEHFRWGKPV. Reading the last three letters gives the tripeptide discussed here.

Alpha msh acts on melanocortin receptors, a family of five G protein-coupled receptors. Pigmentation signaling runs largely through the MC1R subtype.

KPV does not carry the pigment-inducing activity of the parent molecule in the systems tested. That separation of activities is why the fragment became a study object in its own right.

Melanocortin Receptors and What KPV Does Not Target

Receptor pharmacology work published in 2003 dissected the core and C-terminal portions of alpha msh and reported that KPV acts through mechanisms distinct from the anti inflammatory mechanisms of the core melanocortin peptides.

Later murine work found anti inflammatory effects in colitis models that were at least partly independent of MC1R signaling.

Hormone levels of alpha msh in barrier tissue such as gut and skin have been described as part of innate host defense, and that framing first pointed investigators toward the fragment.

The practical reading is that melanocortin receptors are not the whole story for KPV. Intracellular mechanisms and pathways appear to matter more than surface receptor targets.

How KPV Modulates Inflammatory Signaling Inside Cells

The dominant mechanistic account is intracellular rather than receptor-mediated. KPV enters the cell and interacts with inflammatory signaling machinery there.

Cell culture work in Caco2-BBE and HT29-Cl.19A intestinal epithelial lines and in Jurkat T cells, an immune system model line, measured NF-kB luciferase reporter activity after cytokine stimulation.

Nanomolar concentrations lowered reporter activity and pro-inflammatory cytokine transcripts in those cells.

NF-kB as a Master Regulator of Inflammatory Gene Expression

NF-kB is often called a master regulator because it sits upstream of a large block of inflammatory gene transcription. When it is activated, cytokines, chemokines, and adhesion molecules follow and inflammation escalates.

Measuring NF-kB gives a compact readout of inflammatory signaling in a cell line without tracking dozens of downstream products one at a time.

MAP kinase pathways have been measured alongside NF-kB in the same intestinal cells.Both pathways feed the inflammation cascade that colitis models are designed to provoke.

PepT1 and Entry Into Inflamed Epithelial Cells

PepT1 is a proton-coupled di/tripeptide transporter expressed in the small intestine and present at low levels in healthy colon.

Colonic PepT1 expression rises during inflammatory bowel disease. That upregulation is the mechanistic hook: the transporter that carries KPV becomes more available where inflammation is highest.

Uptake experiments using radiolabelled KPV and competition assays support the transporter route directly rather than by inference.

Remove the transporter and the effect disappears. In PepT1 knockout animals, the anti inflammatory effects recorded in wild-type animals did not appear.

Gut Inflammation Research in Laboratory and Animal Models

Gut inflammation is the largest body of work in the gut health literature for this tripeptide. Two chemical colitis models dominate: dextran sodium sulfate and trinitrobenzene sulfonic acid.

Oral KPV was recorded to reduce inflammation and lower colitis incidence in both DSS and TNBS models, read out as decreased pro-inflammatory cytokine expression in colonic tissue.

A second 2008 group tested the fragment in DSS colitis and in CD45RB transfer colitis, a model driven by adoptive transfer of naive T cells rather than a chemical insult.

Histological scoring in that work recorded fewer inflammatory cells infiltrating the tissue and lower severity across the mucosa and the smooth muscle layers beneath it.

Chronic inflammation in these designs is induced deliberately and measured against untreated controls. Nothing in the design speaks to chronic inflammation arising any other way.

Intestinal Inflammation Endpoints and the Gut Barrier

Barrier endpoints sit alongside cytokine endpoints across the gut health literature. Transepithelial electrical resistance and tight junction protein expression are the standard gut barrier readouts for how well the epithelium protects itself.

The gut lining in these models is assessed by permeability measures and by histology of the mucosal surface and the muscle layers under it. Damage to the gut lining is scored, not narrated.

Stomach lining and upper gastrointestinal tissue receive far less attention than colonic tissue. Findings about stomach lining belong to other compounds in the tissue repair literature, not to this one.

Work relevant to digestive issues in the gut health category has concentrated almost entirely on the colon, which is where PepT1 upregulation occurs and where chronic inflammation is modelled.

Inflammatory Bowel Research and Delivery Chemistry

Because the tripeptide is degraded and absorbed before it reaches the colon, a large share of the recent inflammatory bowel body of work is formulation chemistry rather than pharmacology.

Hyaluronic acid-functionalized polymeric nanoparticles loaded with KPV were characterized at roughly 272.3 nm with a zeta potential near negative 5.3 mV.

Those particles were directed toward colonic epithelial cells and macrophages, and the loaded particles were reported as non-cytotoxic in intestinal cells.

In an experimental ulcerative colitis model, the nanoparticle and hydrogel system lowered TNF-alpha, reduced mucosal damage, and shortened mucosal healing time relative to free peptide.

Anti Inflammatory Activity in Skin Conditions Research

Skin is the second barrier organ where the parent hormone is found, so skin work followed the gut health literature closely.

Keratinocytes, dermal fibroblasts, and melanocytes all express components of the melanocortin system, which makes skin tissue a natural site for anti inflammatory activity assays.

Eczema and psoriasis appear here as named model systems and as areas of investigation, not as endpoints KPV has met. Reviews of alpha msh-related tripeptides list skin conditions among proposed directions that the current body of evidence does not yet support.

Inflammatory cells recruited into skin tissue, cytokine profiles, swelling and edema scores, and oxidative stress markers are the measured quantities in these assays. Eczema models rely on barrier and infiltrate endpoints rather than appearance.

Tissue Repair and Wound Healing Endpoints

Wound healing models are where the fragment has been built into hydrogels and other experimental materials. KPV serves as a payload in a matrix rather than as a standalone agent.

Tissue repair endpoints in this work include closure rate in animal research, inflammatory cell counts in the wound bed, and histological quality of the repaired tissue.

Reviews position these as future directions and describe the underlying body of evidence as in vitro, ex vivo, and animal work.

Antimicrobial Endpoints and a Replication Problem

A 2000 study reported that alpha msh and KPV inhibited Staphylococcus aureus colony formation and reduced viability and germ tube formation in Candida albicans, with activity across a broad concentration range including picomolar.

The proposed mechanism was raised intracellular cAMP in the exposed organisms.

A 2009 group attempting to reproduce the Candida work reported no growth inhibition under their conditions, and only a mild effect at 100 micromolar with certain strains.

That disagreement is worth stating plainly, since it sits inside a small body of antimicrobial work. Antimicrobial activity for KPV is a contested finding in the literature rather than a settled one, and the two papers do not support the same conclusion.

Why KPV Is Called a Powerful Peptide Despite Its Small Size

The phrase powerful peptide shows up constantly in secondary write-ups about this anti inflammatory tripeptide. What the primary evidence shows is potency in cell culture at nanomolar concentrations, which is a narrower statement.

Potency in a monolayer assay is a measured endpoint. No evidence supports carrying it across to systems where the compound has not been tested.

Immune system framing follows the same pattern. Cell culture evidence indicates KPV dampens NF-kB-driven inflammation without broadly shutting down cellular activity, which gets summarized as preserving immune function while lowering inflammatory output.

That summary is a fair reading of what protects the immune system profile in a dish and a poor description of anything beyond it. Immune function endpoints in whole animals remain thinner than the cell culture body of work.

Current Status: KPV Is Not FDA Approved

KPV is not FDA approved for any indication. No approved reference pharmaceutical contains this tripeptide, so no approved-product clinical data exists to report.

In 2026 FDA evaluated KPV free base and KPV acetate as bulk drug substances nominated for wound healing and inflammatory conditions. FDA staff identified no published study administering KPV to people and found the characterization record insufficient.

The Pharmacy Compounding Advisory Committee discussed both substances on July 23, 2026. Committee recommendations are advisory, and any listing that would permit use by compounding pharmacies depends on a later FDA determination.

Efficacy data of the kind FDA weighs for approval does not exist for KPV. That absence is the current status, and it is why AZOTH positions this material as research use only.

Nothing above authorizes any use of AZOTH material outside a laboratory. AZOTH supplies KPV as a research chemical with no relationship to any approved article.

Why Researchers Choose KPV from AZOTH

AZOTH supplies KPV to laboratories that need documentation as much as they need material. Every research compound ships with third-party testing records and a certificate of analysis, U.S.-made positioning, and 99%+ purity where documented.

Product specifications cover CAS and molecular formula details, storage conditions, and handling information, so a study protocol can be supported by known parameters rather than assumptions.

The published body of work on this tripeptide is narrow and technical, spanning transporter biology, NF-kB signaling, colitis models, and delivery chemistry. AZOTH publishes educational science at that level rather than translating findings into claims the evidence does not support.

That is the difference from commodity vendors: transparent specifications, testing records, and a premium research-focused customer experience for researchers and science-focused customers.

What the Research Says

The body of evidence for KPV is coherent inside its boundaries and thin outside them. Transporter-mediated entry through PepT1 is well established, and NF-kB modulation in intestinal epithelial cells is reproduced across groups.

Anti inflammatory endpoints in three colitis models point the same direction, with fewer inflammatory cells and lower cytokine output recorded. Each of those animal studies measured the ability of the peptide to reduce inflammation in tissue, and they support further study design and nothing beyond it.

Delivery chemistry is where the newest body of work sits, since the pharmacokinetics of a free tripeptide limit how much reaches the colon intact.

Antimicrobial data remains disputed. Skin conditions work and wound healing work is largely proposal-stage across the gut health and dermatology reviews alike.

FDA’s position is that human exposure data has not been identified. A preclinical body of evidence this size can support hypotheses about gut health and inflammation biology, and it begins rather than ends the scientific record on this peptide.